Literature DB >> 16900012

The prevention and treatment of metabolic syndrome and high-risk obesity.

Behzad Molavi1, Neda Rasouli, Philip A Kern.   

Abstract

PURPOSE OF REVIEW: The prevalence of obesity is increasing at an alarming rate, and the obesity epidemic is driving the epidemic in type 2 diabetes. High-risk obesity is characterized by abdominal obesity with evidence of abnormal glucose and lipid metabolism, and a state of heightened inflammation. RECENT
FINDINGS: With increasing body weight, lipid accumulation occurs not only in adipose tissue, but in other organs as well. This 'lipotoxicity' in liver, muscle, islets, and elsewhere may account for many of the features of the metabolic syndrome. Adipose tissue produces many proteins, some of which are inflammatory cytokines, and others of which are antiinflammatory or which improve insulin sensitivity.
SUMMARY: The treatment of obesity requires the identification of the high-risk patient, and the institution of lifestyle measures with a long-term outlook, and an avoidance of heavily marketed fads. Current research will likely lead to improved medications in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16900012     DOI: 10.1097/01.hco.0000240586.76344.f5

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  9 in total

1.  Metabolic syndrome and obesity in an insect.

Authors:  Rudolf J Schilder; James H Marden
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-28       Impact factor: 11.205

2.  Ceramide is a cardiotoxin in lipotoxic cardiomyopathy.

Authors:  Tae-Sik Park; Yunying Hu; Hye-Lim Noh; Konstantinos Drosatos; Kazue Okajima; Jonathan Buchanan; Joseph Tuinei; Shunichi Homma; Xian-Cheng Jiang; E Dale Abel; Ira J Goldberg
Journal:  J Lipid Res       Date:  2008-05-30       Impact factor: 5.922

3.  Beneficial effects of ketogenic diet in obese diabetic subjects.

Authors:  Hussein M Dashti; Thazhumpal C Mathew; Mousa Khadada; Mahdi Al-Mousawi; Husain Talib; Sami K Asfar; Abdulla I Behbahani; Naji S Al-Zaid
Journal:  Mol Cell Biochem       Date:  2007-04-20       Impact factor: 3.396

Review 4.  Efficacy of Low-Carbohydrate Ketogenic Diet in the Treatment of Type 2 Diabetes.

Authors:  Hussain M Dashti; Thazhumpal C Mathew; Naji S Al-Zaid
Journal:  Med Princ Pract       Date:  2020-10-09       Impact factor: 1.927

5.  β-Lapachone ameliorates lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice.

Authors:  Moon Hee Jeong; Nguyen Khoi Song Tran; Tae Hwan Kwak; Byung Keon Park; Chul Soon Lee; Tae-Sik Park; Young-Hoon Lee; Woo Jin Park; Dong Kwon Yang
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.752

6.  Feeding induced by cannabinoids is mediated independently of the melanocortin system.

Authors:  Puspha Sinnayah; Erin E Jobst; Joseph A Rathner; Angela D Caldera-Siu; Luciana Tonelli-Lemos; Aaron J Eusterbrock; Pablo J Enriori; Emmanuel N Pothos; Kevin L Grove; Michael A Cowley
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

7.  Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity.

Authors:  Hea-Jong Chung; Jae G Yu; In-Ah Lee; Ming-Jie Liu; Yan-Fei Shen; Satya P Sharma; Mohammad A H M Jamal; Jun-Hyun Yoo; Hyeon-Jin Kim; Seong-Tshool Hong
Journal:  FEBS Open Bio       Date:  2016-01-18       Impact factor: 2.693

8.  Effects of isomaltodextrin in postprandial lipid kinetics: Rat study and human randomized crossover study.

Authors:  Ryodai Takagaki; Yuki Ishida; Tsuyoshi Sadakiyo; Yoshifumi Taniguchi; Takeo Sakurai; Hitoshi Mitsuzumi; Hikaru Watanabe; Shigeharu Fukuda; Shimpei Ushio
Journal:  PLoS One       Date:  2018-05-01       Impact factor: 3.240

9.  CCN5 knockout mice exhibit lipotoxic cardiomyopathy with mild obesity and diabetes.

Authors:  Jihwa Kim; Sanghyun Joo; Gwang Hyeon Eom; Seung Hoon Lee; Min-Ah Lee; Miyoung Lee; Ki Woo Kim; Do Han Kim; Hyun Kook; Tae Hwan Kwak; Woo Jin Park
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.